There are currently 2862 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma
NCT06567314
Recruiting
To learn if ivonescimab can help to control advanced cSCC. The safety and effects of ivonescimab will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Cutaneous Squamous Cell Carcinoma
Register for Updates
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients With Advanced Solid Tumors
NCT05932862
Recruiting
This is a FIH, multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as PK and pharmacodynamics of XL309 (previously ISM3091) administered alone or in combination with olaparib in subjects with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Exelixis Clinical Site #1, Houston, Texas +1 locations
Conditions: Advanced Solid Tumor
Register for Updates
Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma
NCT06066359
Recruiting
To find the recommended dose of NY-ESO-1 TCR/IL-15 NK cells that can be given to patients with relapsed or refractory MM. To learn if the dose of NY-ESO-1 TCR/IL-15 NK cells found in Part A can help to control the disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Myeloma
Register for Updates
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
NCT04636814
Recruiting
The purpose of this study is to evaluate the efficacy and the safety of two doses of CHF6001 (Tanimilast) as add-on to maintenance triple therapy in the target patient population.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
03/11/2025
Locations: Chiesi Clinical Trial - Site 840716, Houston, Texas +1 locations
Conditions: Chronic Obstructive Pulmonary Disease
Register for Updates
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
NCT05645718
Recruiting
To learn if cyclophosphamide, vincristine, and dexamethasone (called mini hyper-CVD) in combination with intrathecal (delivered into the spine) chemotherapy (methotrexate, hydrocortisone, cytarabine) and compressed rituximab, blinatumomab, and inotuzumab ozogamicin (called cRIB) can help to control the disease.
Gender:
ALL
Ages:
Between 1 year and 25 years
Trial Updated:
03/11/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Leukemia
Register for Updates
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma
NCT04972942
Recruiting
A Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolescents, and young adults (CAYA) with high risk T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LLy). Pre- and post-HCT NGS-MRD studies will be correlated with outcomes in children, adolescents, and young adults with T-ALL undergoin... Read More
Gender:
ALL
Ages:
39 years and below
Trial Updated:
03/10/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: T-cell Acute Lymphoblastic Leukemia, T-Cell Acute Lymphoblastic Lymphoma
Register for Updates
Remote Game-based Exercise Program for Cognitive and Motor Function Improvement
NCT05235113
Recruiting
As our population ages, more older adults face motor-cognitive declines, increasing their risk of falls and fear of falling. Exercise is an effective way to maintain cognitive function, as supported by recent studies. However, those with poor motor and cognitive abilities often struggle to visit rehabilitation centers, leading to high dropout rates and low adherence to unsupervised programs. A remote exercise program tailored for individuals with cognitive impairments is urgently needed to prese... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
03/10/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Mild Cognitive Impairment, Dementia, Cognitive Impairment, Memory Loss
Register for Updates
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects with Leiomyosarcoma (ARGSARC)
NCT05712694
Recruiting
To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
03/10/2025
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Soft Tissue Sarcoma
Register for Updates
LMN-201 for Prevention of C. Difficile Infection Recurrence
NCT05330182
Recruiting
This is a multisite study to evaluate the safety, tolerability, and efficacy of LMN-201 in participants recently diagnosed with CDI who are scheduled to receive or are receiving SOC antibiotic therapy against C. difficile.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Clostridioides Difficile Infection
Register for Updates
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
NCT06146257
Recruiting
Study GLB-001-01 is a first-in-human (FIH), Phase 1, open-label, dose escalation and expansion clinical study of GLB-001 in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myelodysplastic syndromes (R/R HR-MDS). The dose escalation part (Phase 1a) of the study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-001 administered orally. Approximatel... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: University of Texas M. D. Anderson Cancer Center, Houston, Texas
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Register for Updates
Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry
NCT02249923
Recruiting
Patients are being asked to be in this research study because medical researchers hope that by gathering information about a large number of children with pulmonary hypertension over time, their understanding of the disease process will increase and lead to better treatment. Investigators believe that pulmonary hypertension in children is different than pulmonary hypertension in adults and this study will help us understand those differences.
Gender:
ALL
Ages:
Between 1 day and 21 years
Trial Updated:
03/10/2025
Locations: Texas Children's, Houston, Texas
Conditions: Pulmonary Vascular Disease, Pulmonary Arterial Hypertension
Register for Updates
Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection
NCT05776225
Recruiting
Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Houston Methodist Hospital, Houston, Texas
Conditions: Interstitial Lung Disease, Pulmonary Hypertension
Register for Updates